吉非替尼联合乌苯美司对中晚期非小细胞肺癌患者的临床疗效及免疫功能影响  

The influence of clinical efficacy and immune function of patients with advanced non-small cell lung cancers treated by gefitinib combination ubenimex

作　　者：汪茜茜[1] 王皓[1] WANG Qianqian;WANG Hao(Department of Oncology,Affiliated Yixing Hospital of Jiangsu University,Wuxi,Jiangsu,214200,China)

机构地区：[1]江苏大学附属宜兴市人民医院肿瘤科,江苏无锡214200

出　　处：《当代医学》2021年第5期82-84,共3页Contemporary Medicine

摘　　要：目的探究吉非替尼联合乌苯美司治疗中晚期存在表皮生长因子受体(EGFR)敏感突变的非小细胞肺癌的临床疗效及对免疫功能的影响。方法选取2016年9月至2019年6月本院收治的41例中晚期非小细胞肺癌患者为研究对象,按照随机分组原则分为观察组(n=20)和对照组(n=21)。对照组口服吉非替尼,观察组在对照组基础上联合乌苯美司治疗。比较两组治疗前后免疫功能变化及临床疗效。结果治疗后,观察组外周血中NK细胞占比及CD4+/CD8+比值与治疗前相比均有所升高,且观察组高于对照组(P<0.05);观察组的临床总有效率为70.0%,高于对照组的38.1%(P<0.05)。结论吉非替尼联合乌苯美司可增强中晚期非小细胞肺癌患者的机体免疫力,临床疗效显著,值得临床推广应用。Objective To explore the clinical efficacy and immune function of gefitinib combined with ubenimex in the treatment of advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)sensitive mutations.Methods 41 patients with advanced nonsmall cell lung cancer admitted to our hospital from September 2016 to June 2019 were selected as the research subjects,and were divided into observation group(n=20)and control group(n=21)according to the principle of randomization.The control group took gefitinib orally,and the observation group was treated with ubenimex on the basis of the control group.Results After treatment,the percentage of NK cells and the ratio of CD4+/CD8+in the peripheral blood of the observation group increased compared with those before treatment,and the observation group was higher than that of the control group(P<0.05);the total clinical efficacy rate of the observation group was 70.0%,which was higher than 38.1%of the control group(P<0.05).Conclusion Gefitinib combined with ubenimex can enhance the immunity of patients with advanced non-small cell lung cancer,and has significant clinical efficacy,which is worthy of clinical application.

关 键 词：吉非替尼 乌苯美司 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]